Advances in Virus-Specific T Cell Therapy for Polyomavirus Infections: A Comprehensive Review.

Abstract

Polyomaviruses are a group of small, non-enveloped, double-stranded DNA viruses that can infect various hosts, including humans. BKPyV is known to cause conditions such as human polyomavirus-associated nephropathy (HPyVAN), human polyomavirus-associated hemorrhagic cystitis (HPyVHC), and human polyomavirus-associated urothelial cancer (HPyVUC). JCPyV, on the other hand, is responsible for progressive multifocal leukoencephalopathy (PML), a severe demyelinating disease of the central nervous system. PML primarily affects immunocompromised individuals, including those with HIV, recipients of certain immunosuppressive therapies, and transplant patients. The treatment options for HPyV infections have been limited, but recent developments in virus-specific T cell (VST) therapy have shown promise. While VST therapy has shown promise in treating both BKPyV and JCPyV infections, several challenges remain. These include the time-consuming and costly preparation of VSTs, the need for sophisticated production facilities, and uncertainties regarding the optimal cell type and infusion frequency. To the best of our knowledge, 85 patients with hemorrhagic cystitis, 27 patients with BKPyV viremia, 2 patients with BKPyV nephritis, 14 patients with hemorrhagic cystitis and BKPyV viremia, 32 patients with PML were treated with VST in the literature. The overall response was 82, 33, 35, and 10 complete, partial, non-response, and no-outcome-reported (NA), respectively. In conclusion, this review underscores the importance of VST therapy as a promising treatment approach for polyomavirus infections, emphasizing the need for continued research and clinical trials to refine and expand this innovative immunotherapeutic strategy.